Several large-cap drug stocks registered healthy gains across the third quarter of 2018, signalling investors' growing confidence in biopharma after a disappointing…
Novartis hails the most advanced alpha-directed PI3K inhibitor after success in breast cancer, but it’s not the only one.
Roche targets bispecifics to get ahead in oncology.
A cooling of the M&A climate allows Asia-based groups to come to the fore.
Oncology-focused smaller biotechs reap rich rewards, but generics groups face hard times.
Experts expect Roche's Hemlibra to dominate the inhibitor patient population, but to be a big deal it will need to impress in non-inhibitor patients, too.